
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES211
CHARISMA study
The CHARISMA study did not find a significant benefit associated with clopidogrel plus aspirin as compared with placebo plus aspirin in reducing the incidence of the primary endpoint of MI, stroke, or death from CV causes in patients with clinically evident CVD or at high risk for such disease. Level 1++

[@Bhatt_2006]

